Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials . SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s64, 2022. DOI: 10.25251/skin.6.supp.64. Disponível em: https://skin.dermsquared.com/skin/article/view/1819. Acesso em: 14 may. 2025.